| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Gross Margin | 77.62% | 41.80% | -1927.93% | — | — |
| Operating Margin | -2190.03% | -2237.96% | -61634.47% | — | — |
| EBITDA Margin | -2188.17% | -2208.99% | -61559.32% | — | — |
| Net Margin | -1720.98% | -2325.21% | -63986.48% | — | — |
| Current Ratio | 0.66 | 0.05 | 0.34 | 6.69 | 1.88 |
| Quick Ratio | 0.65 | 0.05 | 0.32 | 6.69 | 1.88 |
| Debt / Equity | — | — | — | — | — |
| ROE | -89.01% | -687.04% | -2663.61% | -59.94% | -236.24% |
| ROA | -56.29% | -208.26% | -42.75% | -51.01% | -110.78% |
| Asset Turnover | 0.03 | 0.09 | 0.00 | — | — |
| Book Value / Share | 16.81 | 3.11 | 0.08 | 1.82 | 0.45 |
Onconetix Inc. is a commercial stage biotechnology company focused on the research, development, and commercialization of proprietary therapeutics, diagnostics, and services for oncology and men's health. It offers Entadfi, an FDA-approved once-daily oral pill combining finasteride and tadalafil for treating benign prostatic hyperplasia, a common prostate disorder. The company also provides Proclarix, an advanced in vitro protein-based blood diagnostic test designed for screening and diagnosing prostate cancer in men with indeterminate Prostate Specific Antigen levels. These products serve clinicians and patients by addressing key needs in prostate health and oncology, including treatment and early detection. Onconetix Inc. pursues partnerships, such as with LabCorp for Proclarix commercialization, to expand access in the United States, European Union, and other markets. Founded in 2018 and headquartered in Cincinnati, Ohio, Onconetix Inc. plays a role in advancing targeted solutions within the biotechnology sector.